Muscarinic Receptor Agonists: Not Created
Equal
|
Schizophrenia Research Forum |
Jul 11 2012 |
| Stealthy Karuna Licenses Schizophrenia Drug from Vanderbilt |
Xconomy |
Sept 28, 2011 |
| Karuna Pharmaceuticals targeting schizophrenia with new discoveries licensed from Vanderbilt University |
The Boston Globe |
Sept 20, 2011 |
| Novel grant supports drug discovery effort |
VUMC Reporter |
Mar 19, 2010 |
| Moving from Theory to Therapy |
Nashville Medical News |
Feb 2009 |
| Vanderbilt Forms Pact With J&J |
Chemical & Engineering News |
Jan 19, 2009 |
| VU, Janssen team in drug discovery effort |
The Reporter |
Jan 16, 2009 |
| Janssen-Vanderbilt; Baxter-Northwestern R&D Pacts Support Idea of Academic Labs as CROs |
Biotech Transfer Week |
Jan 14, 2009 |
J&J, Vanderbilt Team Up on Schizophrenia Drugs
(Alternate PDF Version link) |
Wall Street Journal |
Jan 9, 2009 |
| J&J-Vanderbilt in unusual schizophrenia drug deal |
Forbes.com |
Jan 9, 2009 |
| Fine-Tuning the Design of GPCR Therapeutics |
Genetic Engineering & Biotechnology News |
Oct 15, 2008 |
| A Mind Disabled |
Vanderbilt Medicine |
Summer 2008 |
| Daring to Think Differently About
Schizophrenia |
The New York Times |
Feb 24, 2008 |
| Schizophrenia Treatment Without Side Effects? |
Science |
Sept 4, 2007 |
| Schizophrenia Drug Shows Promise in Trials |
The New York Times |
Sept 3, 2007 |
